These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
614 related items for PubMed ID: 29025709
1. Reduction of In-Stent Restenosis by Cholesteryl Ester Transfer Protein Inhibition. Wu BJ, Li Y, Ong KL, Sun Y, Shrestha S, Hou L, Johns D, Barter PJ, Rye KA. Arterioscler Thromb Vasc Biol; 2017 Dec; 37(12):2333-2341. PubMed ID: 29025709 [Abstract] [Full Text] [Related]
3. The Cholesteryl Ester Transfer Protein Inhibitor, des-Fluoro-Anacetrapib, Prevents Vein Bypass-induced Neointimal Hyperplasia in New Zealand White Rabbits. Wu BJ, Li Y, Ong KL, Sun Y, Johns D, Barter PJ, Rye KA. Sci Rep; 2019 Nov 07; 9(1):16183. PubMed ID: 31700015 [Abstract] [Full Text] [Related]
8. A perlecan-inducing compound significantly inhibits smooth muscle cell function and in-stent intimal hyperplasia: novel insights into the diverse biological effects of perlecan. Segev A, Nili N, Osherov AB, Qiang B, Wong AJ, Pillarisetti S, Strauss BH. EuroIntervention; 2010 May 07; 6(1):134-40. PubMed ID: 20542809 [Abstract] [Full Text] [Related]
14. Association of Serum HMGB2 Levels With In-Stent Restenosis: HMGB2 Promotes Neointimal Hyperplasia in Mice With Femoral Artery Injury and Proliferation and Migration of VSMCs. He YH, Wang XQ, Zhang J, Liu ZH, Pan WQ, Shen Y, Zhu ZB, Wang LJ, Yan XX, Yang K, Zhang RY, Shen WF, Ding FH, Lu L. Arterioscler Thromb Vasc Biol; 2017 Apr 07; 37(4):717-729. PubMed ID: 28183701 [Abstract] [Full Text] [Related]
17. Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib. Johns DG, Chen Y, Wang SP, Castro-Perez J, Previs SF, Roddy TP. Eur J Pharmacol; 2015 Sep 05; 762():256-62. PubMed ID: 26049012 [Abstract] [Full Text] [Related]